It has also been reported in the literature that the mutation status of EGFR/KRAS/ALK/TP53 genes is associated with metastasis in different tissues and organs of lung cancer; in lung adenocarcinoma (LADC) patients, KRAS mutation frequency showed changes related to the metastatic site, and KRAS mutation was associated with significant poor prognosis in cases of bone metastasis.27 This evidence concerns the gene KRAS and lung cancer.